Healthcare AI startup OpenEvidence has raised $250 million in Series D funding at a $12 billion valuation—double its previous valuation. The round was led by Thrive Capital and DST Global.
Key Takeaways
- OpenEvidence raises $250M at $12B valuation
- Valuation doubled from previous round
- Thrive Capital and DST lead investment
- AI platform assists doctors with clinical decisions
Transforming Clinical Decision-Making
OpenEvidence has built an AI platform that helps physicians access and interpret medical evidence at the point of care. The system:
- Analyzes patient data against latest research
- Suggests evidence-based treatment options
- Identifies potential drug interactions
- Stays current with new clinical guidelines
Rapid Growth
The company has experienced explosive growth as hospitals and health systems adopt AI tools. Key metrics include:
- Used by thousands of physicians
- Integration with major EHR systems
- Expansion into multiple specialties
AI Healthcare Investment Boom
OpenEvidence’s raise is part of a broader surge in healthcare AI investment, which reached $10.7 billion in 2025—up 24.4% from the previous year.
Related: Nigerian Healthtech Startup 54gene Secures $45M Series B